An STK19 inhibitor (ZT-012-037-1) was able to inhibit NRAS activation in NRAS-STK19 mutant mice preventing NRAS-driven melanoma development and growth (Yin et al., 2019), revealing a promising therapeutic strategy for NRAS-mutant melanoma tumors treatment (Yin et al., 2019). This evidence concerns the gene NRAS and melanoma.